Gilead stakes claim to full Tamiflu rights

Nine years after inking a marketing deal with Roche for Tamiflu, which has emerged as a frontline drug to prevent the spread of avian flu, Gilead Sciences says it wants the full rights to the drug back. Claiming that Roche has failed to market the drug as it had agreed, Gilead triggered a rare public rumble between two collaborators. Roche, which has struck $1.4 billion worth of supply deals with countries around the globe recently, rejected Gilead's claim and said it would continue to market and sell the drug. Analysts said it was unlikely that Gilead would succeed in regaining control of Tamiflu, but stood to benefit from a settlement of its grievance.

- read this story from the Los Angeles Times for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.